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Abstract
The application of genome editing to animal research connects to a wide variety of policy concerns and public
conversations. We suggest focusing narrowly on public opinion of genome editing is to overlook the range of
positions from which people are brought into relationships with animal research through these technologies.
In this paper, we explore three key roles that publics are playing in the development of genome editing
techniques applied to animals in biomedical research. First, publics are positioned by surveys and focus
groups as stakeholders with opinions that matter to the development of research technologies. Learning
lessons from controversies over genetically modified food in Europe, these methods are used to identify
problems in science–society relations that need to be managed. Second, people are recruited into research
projects through participating in biobanks and providing data, where their contributions are encouraged by
appeals to the public good and maintained by public confidence. Thirdly, patients are increasingly taking
positions within research governance, as lay reviewers on funding panels, where their expertise helps align
research priorities and practices with public expectations of research. These plural publics do not easily
aggregate into a simple or singular public opinion on genome editing. We conclude by suggesting more
attention is needed to the multiple roles that different publics expect – and are expected – to play in the
future development of genomic technologies.
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Introduction
The application of genome editing to animal research
connects a surprisingly diverse set of policy concerns
and public conversations. Initial plans to do research
using genome editing techniques could be reviewed by a
patient volunteer sitting on a funding panel, who is
attuned to the public priorities and purpose of the
research. The project licence application will be
reviewed by a local animal welfare and ethical review
board, where there is likely to be a lay representative
speaking about social perspectives on acceptable
animal use. The research itself may involve screening
animal phenotypes through protocols devised by gath-
ering patient experiences from surveys administered
through clinical practice. The ultimate clinical develop-
ment and implementation of therapeutic products will
depend on recruitment of people into clinical trials to
test safety and efficacy, but also on there being a wider
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publicly acceptable regulatory framework underpin-
ning this use of animals in research. At each point
there are different public interests and there will be
different public views. The social aspects of applying
genome editing to animal research are both distributed
and diverse, meaning they are demanding for policy
makers and practitioners to pull together.
The Royal Society1 and the Nuffield Council for
Bioethics2 recently published their public dialogues on
the social aspects of genome editing. These show the
wide range of social concerns around genome editing
and demonstrate how different methods for engaging
people in dialogue shape how they talk and think about
issues. This adds further methodological complexity to
the diversity of roles people play. Social scientists have
long argued that public opinion on new technologies
does not reflect pre-existing individual attitudes; rather
attitudes emerge from the way institutions and meth-
ods seek to engage people and their everyday experi-
ences.3,4 Social science methods, policy dialogue and
media campaigns all structure how public voices and
interests are expressed and heard.4,5 Looking at how
these publics take shape is important for devising meth-
ods that engage people in genuine dialogue with the
emerging technologies affecting them.
In what follows we unpack three key roles that pub-
lics are playing in conversations about genome editing
applied to animals in biomedicine: as stakeholders,
populations and participants in research. In each
case, we explore how different research techniques are
used to recruit and represent these publics, focusing on
surveys and public dialogue, biobank participation and
patient involvement. We consider the continuities
between past debates on genetic modification, which
took place from the late 1990s and focused on gene
patenting, transgenics and cloning,6 and the results of
polls and public dialogue methods used to assess public
views around genome editing today. We also trace the
new ways people are involved in the interfaces between
animal research and genome editing, through contrib-
uting data to biobanks and patient involvement. We
draw on collaborative work within the Wellcome
Trust funded Animal Research Nexus programme7 to
map out these different public interfaces, focusing
mainly on the UK. The multiple roles that publics
play in the future development of genome technologies
will differ internationally, but this complexity will be
found everywhere in different configurations.
Searching for the public
We start with the assertion ‘the public’ is not something
pre-existing but is something that is called into being
and always encountered in mediated forms.8 We do not
dismiss terms like ‘public opinion’ or the ‘public
interest’, but we do want to contextualise them. In lib-
eral democracies, we recognise we are talking about
something important when we talk about the public
interest, identifying an issue that matters to everyone,
requires collective decisions, and warrants public
debate.9 The aspiration to record what the public
thinks about animal research and genome editing
reflects these important values. Yet to search for the
public view on something is to pursue a mirage; it fades
as we get closer to it. Members of the public may be
asked their opinions through a variety of methods –
such as surveys, interviews, or focus groups – carried
out by a range of researchers – in academic institutions,
market research, or policy contexts. That this gives rise
to a diversity of views is generally accepted and the
earlier literatures on genetic modification of animals
indicate there are differences by gender, age, occupa-
tion and education.10 However, there are further differ-
ences that make aggregation hard. Members of the
public may respond to surveys that position them as
citizens. They may also contribute to the policy and
practice of genome editing through engaging in consul-
tations, sitting on ethics committees, participating in
preclinical research, or campaigning in groups, speak-
ing in different ways that reflect these particular
contexts.
Using the plural term ‘publics’ recognises the demo-
graphic differences and divergent opinions around a
controversial topic like animal research. It also incor-
porates the way people speak and act from different
positions when they make their views public. You can
see this through considering what social scientists call
everyday ‘speech acts’.11 When asked their opinion,
people often use phrases such ‘as a parent’, ‘as a local
resident’, or ‘as a taxpayer’. Each is a different kind of
public voice, located in different relationships and com-
munities, with different expectations of the people and
institutions they are speaking to. We may use terms in
sequence to express ambiguity: ‘as a consumer, I do not
want to pay more for the food I need to feed my
family’, but ‘as a pet owner, animal welfare is impor-
tant’. Through speaking, we are also acting, declaring
what we care about, and what we want other people or
authorities to do to align with our expectations – here
provide affordable food, whilst protecting animal wel-
fare. Personal actions follow similar patterns: we do
and ask for different things when we understand our-
selves as citizens, consumers, carers, or patients. We
may also emphasise different aspects of these identities
when research methods engage us as individuals (as in
questionnaire surveys or polls) or as part of social
groups (as in focus groups or committees).
Advertisers, campaigners and politicians appeal to
these different facets of our lives, giving rise to
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stratified, contradictory, and sometimes polarised
public groups, or publics.
Understanding these diverse publics is vitally impor-
tant to the unfolding politics and practice of genome
editing. The development of genetic engineering – from
transgenics to CRISPR/Cas technologies – has been
accompanied by social research techniques for engag-
ing publics in dialogue with its changing aspirations
and implications.12–14 The Eurobarometer surveys
have been polling publics on scientific issues since the
1990s,15 with a Special Eurobarometer on the genetic
alteration of animals in 2010.16 These methods are used
to measure opinion, monitor long-term trends and
identify problems in science–society relations so that
they may be resolved. The 2014 UK’s Ipsos MORI
finding that the bioscience sector was seen as secretive
and untrusted17 led to the Concordat on Openness in
Animal Research, with signatories committing to pro-
viding ‘clear, transparent and open communication and
proactive public engagement on this subject’.18
Regular polls on animal research have also been a
significant resource for regulators, scientists and cam-
paigning groups. These opinion polls indicate the con-
tinual conditionality of public support for animal
research, where there are no alternatives and research
is essential, and the variations in public trust and opti-
mism over time.17,19 As Hobson-West explains, opin-
ion polls are valued for making public views around
this contentious issue tractable and conferring moral
legitimacy and democratically accountability to those
looking to evidence public views on animal research.20
Polls are important means of constructing the public
view of both genome editing and animal research, but
they are framed by institutional questions and present a
partial picture of what matters to people. They can be
supplemented by qualitative research showing how
people talk about the genetic modification of animals,
and what they are asking of others, in social contexts
and conversations.
Finding common concerns
Smith and Samuel currently suggest ‘non-human
Genome Editing is a “technical category” but not a
“public topic”’.21 They emphasise that ongoing expert
discussions about technical and policy issues are not
yet matched by public debate about genome editing
and animals. Yet there are periods when the genetic
alteration of animals has become a public topic from
the first genetically modified organisms (GMOs) in
1973 to the present. These cycles of public interest
follow scientific developments, non-governmental
organisation campaigns, legal challenges and policy
engagements. They often focus on charismatic animals,
which capture media attention, or contentious issues,
which fit existing media scripts about scientific inter-
vention and control. The patenting of OncoMouse,22
the cloning of Dolly the sheep,23 the stops and starts of
xenotransplantation,24,25 the regulatory challenge of
hybrid embryos26 and the future potential of gene
drives27 have all become public topics since the 1990s,
accompanied by opinion polling and qualitative social
research. Despite the changing focus of debates, these
conversations share many characteristics as they are
mediated through everyday experiences and media
narratives.
In the early 2000s, Macnaghten28 ran focus groups
exploring public attitudes and sensibilities towards ani-
mals and biotechnology in the UK. People’s concerns
reflected how they valued animals in their everyday
lives. They were worried genetic engineering would
change animals ‘in their nature’, even unmooring
their sense of the intrinsically ‘right’ way of being for
animals. The use of animals in research was so far
removed from everyday engagements with animals
that many people did not want to think about it, but
this did not indicate a lack of concern. All had their
own understandings of care and responsibility, though
there were differences between pet owners, wildlife
enthusiasts, farmers, hunters and others. The genetic
engineering of animals was more acceptable for medi-
cal uses than food, something also heard in debates
about genetically modified plants, but the boundaries
between the two were not seen as static or unalterable.
The apparently contradictory values people have about
different animals, derived from everyday experiences, is
a common finding.
As people consider the ethical challenge of changing
an animal’s genome, they also draw on a set of recur-
ring vocabularies. Naturalness is a problematic catego-
ry to define, but it is a recognised language through
which people express ethical concerns.6 Phrases like
‘playing god’ or ‘going against nature’ are often dis-
missed as emotive or empty rhetoric,29 but a detailed
look at these speech acts shows they are personally
meaningful moral expressions and communicate views
about institutional responsibility.25 People draw on
common cultural images to raise questions about sci-
entific and regulatory control. Frankenstein’s monster
often accompanies genetic debates and is used by pub-
lics, campaigning groups and others to raise issues
around accountability.30 Recent work on genome edit-
ing suggests similar issues of naturalness, trust and pur-
pose do arise, though they also indicate potential
differences by pointing to the greater precision and
lack of species crossing in genome editing,6 something
stressed to secure public consent.
Whilst many people resist thinking about animals as
means to an end, the proposed purpose of genetic alter-
ation is an enduring aspect of public concern. Studies
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since the 1990s repeatedly present evidence that the
genetic alteration of organisms is more acceptable for
medical developments than for agricultural purposes,12
in secure laboratories than open environments,31 and
for societal benefits than for commercial gain.12
Cloning was seen as particularly troubling as its end
purpose was not clear.15 People also expect these
debates to be held in public and excluding them, for
reasons of confidentiality or security, diminishes trust
in both scientific and regulatory control.6 Whilst opin-
ion polls have provided institutionally useful summa-
ries of public views on genetic engineering in the past,
qualitative research has helped show how these views
are formed in relation to everyday experiences and
shifting institutional conduct. Many of these patterns
can be seen in the publics emerging around genome
editing today.
The emergent publics of genome editing
Publics as stakeholders
Public engagement around genome editing is now seen
as a priority for policy makers.2,32 Questions on the
subject increasingly appear in opinion polls, as in the
2019 instalment of the UK Government’s ‘Public
Attitudes to Science’ survey.33 There are also a growing
number of dialogue events examining how people talk
about genome editing. So far, lay discussion ‘if it
occurs, appears to be predominantly invited and in
formal spaces’.21 One example is the 2017 Royal
Society’s public dialogue, which consisted of three
deliberative workshops and a national survey.2 The
workshops sought to identify ‘the frames and contexts
that moderate the public acceptability of developing
UK research into genetic technologies’, whilst the
survey aimed to provide ‘clarity on the applications
that a majority of the public do or do not support,
why and under what conditions’.1 This process indi-
cates the complex role of the public here: it recognises
the public stakes in genome editing, the importance of
having debates in public, and the legitimacy conferred
by measuring public opinion.
However, looking closely at how different aspects of
this process were organised helps explain why these
different versions of the public do not always align.
The Royal Society survey excluded those with ‘a pro-
fessional stake in genetic technologies (e.g. clinicians,
academics and policy makers in the field)’.1 Members
of animal rights and welfare groups have historically
also been screened out of public opinion polls concern-
ing animal research.19 Excluding those with explicit
interests or knowledge creates a version of the public
that is seen as statistically unbiased, but also largely
uninformed. Perhaps not surprisingly many polls then
identify the public as ‘deficient and misguided’34 in
their understanding of science. As Wehling observes,
screening can hamper successful public participation
by suppressing ‘precisely those attributes which would
enable civil society actors to make meaningful
contributions’.35
With few everyday contexts to ground discussions of
non-human genome editing at present, the exclusion of
those with existing knowledge makes public opinion
more tractable, but it attenuates debate. The Royal
Society workshops aimed to recruit ‘10% of people
who have a specific interest in the application of genetic
technologies under discussion to ensure it was an inclu-
sive process encompassing a wide range of views’.1
However, these are seen as interest groups, not the
view of ‘the public’. By pluralising publics social scien-
tists acknowledge the different positions on issues such
as genome editing and call for methods that account
for and engage with this diversity.
Publics as populations
Ethical debates around genome editing in biomedicine,
which focus on issues of public good and the solidar-
ities that promote research participation,36,37 have had
less visibility in discussions of animal research.
Mulvihill et al. suggest genome editing does not pro-
duce substantively new ethical issues in medicine, but
the explosive rate of new findings, unrealistic expect-
ations of professions and publics, and additional com-
mercial imperatives does.36 Genome editing brings new
contact points between publics and animal research
through translational genomics, tissue biobanks and
data intensive science. These seem far removed from
conventional public controversies around animal
research, but these publics are central to realising the
promise of genome editing. They also raise familiar
questions about how potential harms are controlled
and benefits distributed, and similarly depend on
public trust and ideas of collective good.
More people are now taking part in large-scale proj-
ects that involve animal research, such as the 100,000
genomes project,38 or contributing to biobanks, such as
the UK Biobank.39 These aim to create collections of
populations or rare diseases by inviting individuals to
donate biological samples and permit access to health
records and other data. These may be used in biomed-
ical research involving animals, such as improving
animal models40 or combining data from human and
animal studies.41 This is a less visible but more direct
form of public engagement with science than contrib-
uting to a public dialogue. It also depends on a new
notion of the public as ‘people with data’.42 This means
changing methods for engaging publics from techni-
ques that monitor public attitudes to research over
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time to processes that realise the value of people’s
health knowledges to support cross species translation-
al research. Campbell suggests participating in these
projects requires ‘a major and long-term commitment
[which] must depend on both a strong motivation to
assist in the project and a high level of trust’,43 over and
above that required for other forms of scientific partic-
ipation.43,44 Carefully targeted public engagement is
essential for successful recruitment; socially acceptable
ethical processes for consent, feedback and access, and
agreement on how the biobank is used.43,45
Yet, there is a cross-over between engaging individ-
uals as ‘people with data’ and the broader public inter-
est. Biobanks construct publics as sample populations
through appealing to notions of public good to solicit
contributions and draw on local historical and political
contexts to produce appropriate governance.46 The UK
Biobank’s recruitment strategy involves appeals to
ideas of ‘social solidarity embodied in the welfare
state and the National Health Service’,39 invoking cit-
izenship rather than personal health concerns to
encourage and sustain participation. The people and
patients contributing data and samples are important
to realising future benefits from genome editing.
Ongoing public trust in biobanks depends on many
factors also important to public confidence in animal
research including motivation, openness and gover-
nance.47 Many biobank–public interfaces are currently
‘simply unexplored’ or the data is ‘inconsistent’.48 We
suggest more attention could be given to biobank par-
ticipants as one of the publics assembled around
genome editing and animal research to acknowledge
their importance and explore how far biobank engage-
ment depends on sustaining trust as rates of research,
unrealistic expectations and commercial imperatives
expand across related areas of science.
Publics as participants
Other publics are more explicitly involved in shaping
the priorities and practices of animal research. Patient
and public involvement (PPI) is increasingly formalised
within the funding, development and governance of
health research49 and is recognised as a priority for
genomics research.50 In PPI, publics are invited to co-
produce all aspects of research, from setting research
priorities to facilitating clinical trials. Early work by
AIDS activists in the USA and the UK challenged
researchers’ approaches to conducting trials that over-
looked patients’ preferred outcomes.51 Further PPI has
led to recognition of the ‘expert patient’ or ‘expert-by-
experience’52 and patients are increasingly valued by
researchers for their personal knowledge of their
health conditions.53 Patient involvement can enable
researchers to concentrate on the issues that matter to
people,54 reduce research waste and build science that
commands public trust.55 The Alzheimer’s Society, for
example, suggest their patient involvement helped
understand the ‘real world’ realities of dementia,
enhance the validity of their methods, produce more
useful and relevant outputs, and better navigate ethical
issues and approvals.56 Advocacy groups also play an
increasingly important role in collaborating with
researchers, shaping the availability of research funding
for things like rare diseases,57 to the extent that this
public sociality can be seen as driving science.58
The abstract figure of ‘the patient’ has long been a
powerful actor in arguments around animal research,
but this has mostly involved them being ‘spoken for’
by advocates of animal research, rather than represent-
ing their own lived expertise.59 PPI repositions patients
from health consumers to being ‘involved in all stages of
research’,51 including in discussions about genome edit-
ing and animal research,50 though some PPI may be
motivated by efforts to secure legitimacy or funding,
rather than opening up decision-making. However,
members of the public are likely to be actively involved
in making future decisions about genome editing,
influencing what research is funded and prioritised, as
well as in the dissemination of results.50 PPI does not
involve ‘lay’ stakeholders acquiring equivalent expertise
to researchers, or speaking for all patients. Yet even in
this specific context, the fact people are playing different
roles is evidenced by the diverse terminologies used to
define their involvement as ‘volunteers’, ‘consumers’
and ‘lay-members’ across different organisations.
Our own work has traced how people who are
patients or carers involved in PPI manage their com-
plex positions when reviewing and monitoring projects
involving animal research.60 They may draw on person-
al or family health experiences, speak for patient com-
munities, ask questions about animal care, or seek to
offer public assurance around the regulation of animal
research and welfare.60 The lines between public and
personal interests become increasingly blurred. People
draw on personal associations even when expressing
‘civic’ concern,61 and patients given personal access to
animal research take their public responsibilities seri-
ously.59,60 These expert patients are very different to
the autonomous individual who is the imagined target
of much public engagement or surveys, but they can
make valuable contributions to the ‘knowledge engage-
ment’ required to realise public benefits from genome
editing using animals.27
Discussion
The different publics and qualities of ‘publicness’62 out-
lined above are useful for considering why, how and
when to involve publics in discussions about the
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application of genome editing to animal research. They
help describe why diverse public views do not easily
aggregate into a picture of what the public thinks
about genome editing and explain how contradictory
societal perspectives emerge from everyday experiences.
They assist in identifying different ideas of public inter-
est and the public good that underpin processes used to
engage people. They also demand that those seeking to
capture public views are clear about why they are doing
this, how to do it, and how to use them. Efforts to
measure public views change who makes up the
public, what is the public interest, and how people
respond.
However, this is not to promote only diversity or
suggest public opinion surveys have no value.
Following Dewey,63 we suggest well-crafted surveys
can serve citizenship functions by creating discussion
of what public opinion is or might be. A well-crafted
survey would be explicit about how it is claiming to be
representative of the perspectives around animal
research, whether through prioritising demographic
characteristics,17 patient views,64 or the range of posi-
tions on animal use,65 and reflexive about how these
contribute to different notions of the public interest
around animal research. We also argue that there are
important commonalities in how people talk about
genome technologies, which reflect how debates take
place in the public domain. Some of this convergence
results from the way public debates around science are
mediated by similar research methodologies and media
narratives, but it is also shaped by what people consis-
tently value in their everyday lives, and their expecta-
tion that others will act in a capacity that is
trustworthy. These insights can be used to nurture
more positive knowledge exchange between patients,
biobank participants, publics and scientists.
As the scope of genome editing expands, so does the
diversity of issues and people it affects and involves,
requiring new understandings of how to engage these
emerging publics. We would follow Hartley et al. in
calling for processes that maximise knowledge engage-
ment across diverse publics, rather than simply public
engagement.27 New forums are required to work with
the diversity of publics, nationally and internationally,
including all participants in reflexive exploration of
‘what questions should be asked, whose views must
be heard, what imbalances of power should be made
visible, and what diversity of views exist’.66 In taking
approaches that reflect carefully, critically and contex-
tually on their methods, efforts to understand public
opinion can more constructively recognise how geno-
mic editing is made meaningful and at times problem-
atic in the everyday.
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Resume
L’application de l’edition genomique à la recherche sur les animaux est liee à une grande variete de
preoccupations strategiques et de conversations publiques. Nous suggerons que se concentrer etroitement
sur l’opinion publique de l’edition genomique revient à negliger l’eventail de positions à partir desquelles les
gens sont amenes à la recherche animale par le biais de ces technologies. Dans cet article, nous explorons
trois rôles cles que jouent les publics dans le developpement des techniques d’edition genomique appliquees
aux animaux utilises dans la recherche biomedicale. Premierement, les publics sont positionnes par des
enquêtes et des groupes de discussion comme des intervenants ayant des opinions importantes pour le
developpement des technologies de recherche. En tirant des leçons des controverses que suscitent les
aliments genetiquement modifies en Europe, ces methodes sont utilisees pour identifier les problemes
lies aux relations science-societe qui doivent être geres. Deuxiemement, les personnes sont recrutees
dans des projets de recherche en participant à des biobanques et en fournissant des donnees, ou leurs
contributions sont encouragees par des appels au bien public et maintenues par la confiance du public.
Troisiemement, les patients prennent de plus en plus de positions dans le domaine de la gouvernance de la
recherche, en tant qu’examinateurs externes de comites de financement, ou leur expertise aide à aligner les
priorites et les pratiques de recherche sur les attentes du public à l’egard de la recherche. Ces publics
pluriels ne se regroupent pas facilement en une seule opinion publique simple ou singuliere sur l’edition
genomique. Nous concluons en suggerant qu’il est necessaire d’accorder plus d’attention aux rôles multiples
que les differents publics s’attendent à jouer – et à ceux que l’on s’attend à ce qu’ils jouent – dans le
developpement futur des technologies genomiques.
8 Laboratory Animals 0(0)
Abstract
Zur Anwendung der Genom-Editierung in der Tierforschung gibt es viele politische Bedenken und €offentliche
Debatten. Wir geben hier zu bedenken, dass bei einer einseitigen Berücksichtigung der €offentlichen Meinung
zur Genom-Editierung eine ganze Bandbreite an Positionen außer Acht bleibt, auf deren Grundlage Menschen
durch diese Technologien einen Bezug zur Tierforschung erlangen. In diesem Beitrag untersuchen wir drei
Schlüsselrollen, die die €Offentlichkeit bei der Entwicklung von Genome-Editing-Techniken spielt, die in der
biomedizinischen Forschung bei Tieren zum Einsatz kommen. Erstens positionieren Umfragen und
Fokusgruppen die €Offentlichkeit als Beteiligte mit Meinungen, die für die Entwicklung von
Forschungstechnologien von Bedeutung sind. Unter Nutzung der aus den Kontroversen um gentechnisch
ver€anderte Lebensmittel in Europa gezogenen Lehren werden diese Methoden genutzt, um Probleme in den
Beziehungen zwischen Wissenschaft und Gesellschaft zu identifizieren, die es zu bew€altigen gilt. Zweitens
werden Menschen für Forschungsprojekte rekrutiert, um an Biobanken teilzunehmen und Daten zur
Verfügung zu stellen, wobei ihre Mitwirkung durch Appelle an das Gemeinwohl gef€ordert und durch
€offentliches Vertrauen gew€ahrleistet wird. Drittens nehmen Patienten zunehmend Positionen in der
Governance-Forschung ein, z. B. als Laiengutachter in Finanzierungsgremien, wo ihr Fachwissen dazu
beitr€agt, Forschungspriorit€aten und -praktiken mit den €offentlichen Erwartungen an die Forschung in
Einklang zu bringen. Diese Bandbreite €offentlicher Meinung l€asst sich nicht ohne weiteres zu einer einfachen
oder singul€aren €offentlichen Meinung über Genome Editing zusammenfassen. Wir ziehen daher abschließend
das Fazit, dass den vielf€altigen Rollen, die verschiedene Teile der €Offentlichkeit bei der zukünftigen
Entwicklung von Genomverfahren erwarten – und von denen erwartet wird, dass sie sie wahrnehmen –
mehr Aufmerksamkeit zuteil werden muss.
Resumen
La aplicacion de la edicion genomica en la investigacion animal conecta con una amplia variedad de temas de
polıticas y conversaciones publicas. Pensamos que centrarse limitadamente en la opinion publica de la
edicion genomica es ignorar la gama de puestos desde los que la gente entra en contacto con la investigacion
animal a traves de estas tecnologıas. En este estudio, exploramos tres funciones principales que el publico
está desempe~nando en el desarrollo de tecnicas de edicion genomica aplicadas a animales en la inves-
tigacion biomedica. En primer lugar, el publico se posiciona mediante encuestas y grupos de debate como
actores con opiniones que son importantes para el desarrollo de tecnologıas de investigacion. Tras aprender
de distintas controversias sobre alimentos modificados geneticamente en Europa, estos metodos se utilizan
para identificar problemas en las relaciones de la ciencia con la sociedad que tienen que gestionarse. En
segundo lugar, la gente es reclutada para proyectos de investigacion mediante la participacion en biobancos y
suministrando datos, donde se fomenta su contribucion mediante llamadas al bien publico y se mantiene con
la confianza del publico. En tercer lugar, los pacientes cada vez están consiguiendo puestos dentro de la
gobernanza de la investigacion, como revisores de colocaciones en paneles de financiacion, donde su pericia
ayuda a alinear prioridades y prácticas de investigacion con las expectativas que el publico tiene en la
investigacion. Este publico plural no se conjuga fácilmente en una opinion publica simple o singular sobre
la edicion genomica. Concluimos este estudio sugiriendo una mayor atencion en las multiples funciones que
diferentes publicos esperan desempe~nar (y que se espera que lo hagan) en el futuro desarrollo de
tecnologıas genomicas.
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